中文

上海医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-30
ItemAmountY/Y
Revenue¥75.26B+6.4%
Gross profit¥8.09B
Operating income¥2.41B
Net income¥1.85B+12.8%
Gross margin10.8%Net margin 2.5%
Revenue Q/Q+9.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥67.17B89.2%
R&D¥0.47B0.6%
SG&A¥4.59B6.1%
Tax & other¥0.56B0.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

中国中冶中国人寿长城汽车邮储银行中国建筑中国电建华泰证券拓普集团中国卫通上海电气中国电信中国中车

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies